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Purpose. Screening for depression, sleep-related disturbances, and anxiety in patients with diagnosed adenocarcinoma of the
pancreas. Materials and Methods. Patients were evaluated at initial consultation and subsequent visits at the multidisciplinary
pancreatic cancer clinic at our University Cancer Center. Cross-sectional and longitudinal psychosocial distress was assessed
utilizing Personal Health Questionnaire 9 (PHQ9) to screen for depression and monitor symptoms, the Penn State Worry
Questionnaire (PSWQ) for generalized anxiety, and the University of Michigan Sleep Questionnaire to monitor sleep symptoms.
Results. Twenty-two patients diagnosed with pancreatic cancer participated during the 6-month pilot study with longitudinal
followup for thirteen patients. In this study, mild-to-moderate depressive symptoms, anxiety, and potential sleep problems were
common.Themainﬁndingofthestudywas23%ofthepatientswhowerepartofthispilotprojectscreenedpositiveformoderately
severe major depressive symptoms, likely anxiety disorder or a potential sleep disorder during the study. One patient screened
positiveformoderatelyseveredepressivesymptomsinlongitudinalfollowup. Conclusions.Depression,anxiety,andsleepproblems
are evident in patients with pancreatic cancer. Prospective, longitudinal studies, with larger groups of patients, are needed to




States [1] with a ﬁve-year survival for all stages of 5%. Even
for localized, resectable pancreatic cancer, the mean life
expectancy ranges from 15 to 19 months [2]. With such
a short life expectancy, health-related quality of life is an
important aspect of care in these patients. Screening for dis-
tress in pancreatic cancer patients is increasingly assessed in
clinical trials but has not become a standard component of
routine clinical care. The National Comprehensive Cancer
Network has implemented clinical practice guidelines in
distress management of patients with cancer [3]. In order
to incorporate these recommendations into clinical care,
knowledge of the prevalence and spectrum of distress and
its eﬀect on quality of life in patients with newly diagnosed
adenocarcinoma of the pancreas is necessary.
We have recently reviewed the association of pancreatic
cancer with depression [4]. Pancreatic cancer is commonly
perceived by the public of being a painful and deadly disease,
which leads to fear in patients diagnosed with pancreatic
cancer that might lead to anxiety and depression [5].
Depression in pancreatic cancer has been reported to have
a higher prevalence than in patients with other types of gas-
trointestinal carcinomas [6]. The range of reported depres-
sion varies widely, from 10% to 75%, depending on the
instrumentsusedforevaluationandwhentheevaluationwas
performed relative to diagnosis and treatment [7–13]. While
the link has been known for ages, the relationship is still
poorly understood and understudied [14, 15]. Recentstudies
evaluating patient-reported outcomes list depressive symp-
toms at 40% for pancreatic cancer [13]. Depression and
anxiety may even precede the diagnosis of pancreatic cancer.
Anxiety, including presentation with panic attacks, has been
reported prior to the diagnosis of pancreatic cancer [16, 17].
An investigation of signs and symptoms of pancreatic cancer
by a population-based case-control study found that patients
with pancreatic cancer were more likely to report altered
ability to sleep than controls (OR, 2.9; 95% CI: 1.3–6.3) [18].
Althoughpainhasbeenexaminedasacorrelateofdepression
[19],itappearsthattheremaybe aphysiologiccauseforpain
as well [20]. However, the details and spectrum of psychoso-
cialdistressanddepressioninpancreaticcancerpatientshave
not been fully investigated. A recent review conﬁrmed the
linkage between pancreatic cancer and depression but was
unable to explain the cause or a direct coping style aﬀecting
survival [21]. An analysis of 50 inpatient pancreatic cancer
inpatients in China revealed that the link between depression
and pancreatic cancer is common [22] .Ar e c e n tp o p u l a t i o n
analysis in the Netherlands of 120,852 individuals found a
modest decrease in risk of pancreatic cancer associated with
past sports activity [23]. However, a prior systematic review
did not ﬁnd a strong evidence of a link with physical activity
and pancreatic cancer [24].
A particular association of depression with pancreatic
carcinomahasbeenpreviouslyproposed,withYaskinreport-
ing depression, anxiety, and insomnia as the presenting
symptoms for pancreatic cancer as early as 1931 [25]. When
compared with patients with gastric adenocarcinoma, pan-
creatic cancer patients were more likely to fulﬁll criteria for
major depressive disorder within one year prior to diagnosis
or at the time of diagnosis [26, 27]. A population-based case-
control study found that there was an increase in altered
ability to sleep (OR, 2.9, 95% CI, 1.3–6.3) reported in cases
compared to controls within 3 years before diagnosis with
pancreatic cancer [18]. Additionally, a relationship between
depression and pancreatic cancer was found in the general
population using a longitudinal population-based study
[28] with depression more commonly preceding pancreatic
cancer than other malignancies (OR 4.1, 95% CI, 1.05–
16.0). Taken together, these data suggest that the relationship
between depression, anxiety, insomnia, or sleep related
disturbancesandpancreaticcancerislikelytobeduetomore
thanpoorprognosisorfearofpain[5].Thedataofthisstudy
does reveal a prevalence of the comorbid conditions but does
not add additional insight to the cause of that interrelation-
ship.
Anotherareaofrecentinterestistherelationshipbetween
sleep and cancer [29]. The symptom-based approach focuses
on the insomnia and daytime sleepiness [29]. A case report
of abnormal sleep behavior, similar to sleep-related epilepsy,
parasomnia, and night delirium, became a subsequent
diagnosis of a tumor in the pancreas [30]w h i c hd e m o n -
strates how sleep disturbances can precede the diagnosis.
Moreover, self-reported sleep disturbances increase during
chemotherapy in pancreatic cancer patients [31]. However,
the relationship among depression, sleep, and anxiety treat-
ment side eﬀects and response is complex and has not been
adequately studied in pancreatic cancer. The objectives of
this pilot study were to evaluate the symptoms of depression,
sleep, and anxiety disorders in a cross-sectional and longi-
tudinal study in patients presenting to a multidisciplinary
pancreatic cancer clinic. In addition, we wanted to evaluate
the feasibility of patient’s direct entry of data into an
electronic data management system. While larger studies
have examined a single psychiatric conditions, due to the
overlapping of symptoms and possible biological basis of
sleep, depression and anxiety this pilot project were initiated
to evaluate the co-morbidities with pancreatic cancer.
2.MaterialandMethods
Over a six-month study period, 27 patients presenting to the
University of Michigan Multidisciplinary Pancreatic Cancer
Clinicwereapproachedtoparticipateinthestudy,whichwas
approved by the University of Michigan Institutional Review
Board. The exclusion criteria were inability to communicate,
understand verbal or written English. Individuals were
approached during their initial consultation appointment by
the project coordinator. As this study was designed to be
conducted in conjunction with the clinic visit, a number
of stipulations were imposed on this study by both the
Comprehensive Cancer Center and the Internal Review
Board to protect the patients. The treating clinical providers
were the ones who referred the patients to the research staﬀ.
Twenty-fourpatientsprovidedwritteninformedconsentand
completed at least one assessment. A total of 3 people wereThe Scientiﬁc World Journal 3
approached and turned down the research team, and two
other patients without pancreatic cancer were not included
inthestudy.22researchsubjectssubsequentlyhadconﬁrmed
pancreatic cancer, who were included in the analysis. The
Personal Health Questionnaire 9 (PHQ9) [32] was utilized
to screen for depression and to monitor symptoms during
the course of care. Subjects completed the Penn State Worry
Questionnaire (PSWQ) [33] for generalized anxiety. The
University of Michigan Sleep Assessment Questionnaire was
utilized to monitor sleep symptoms. Patients were evaluated
at their intake consultation and at subsequent follow-up
visits during the study period not frequently than once a
month for the complete duration of the 6-month project.
Any patient who screened positive for depression, sleep
disorder, or anxiety had clinical followup by the clinic
physician, a visit by the clinical social worker, or a referral to
a psychiatrist. In addition, all patients received information
about the psychooncology program at the cancer center. One
goal of the study was to repeat the measurements over time.
Since the same psychometric surveys would be conducted
multiple times, a restriction of completing all of the tests
within 30 minutes was imposed. Other psychometric tests
were not permitted due to the length of time to complete the
alternative psychometric tests. During the study, the research
team was restricted to approaching the research subjects to
once a month so as not to burden the research subjects.
In order to facilitate collection of data and incorporation
into an electronic record, subjects initially utilized a tablet
personal computer with export of the data into the M-
STRIDES clinical server [34]. This server was designed for
intake screening for the Department of Psychiatry and also
containsanumberofpsychometricsurveyswhicharepatient
administered for longitudinal followup. The research sub-
jects were told that the survey data would become part of
the clinical record. If there was diﬃculty with data entry by
subjects, hard copy questionnaires were utilized by research
subjects, and the data was subsequently entered by research
assistants.
2.1. Statistical Analysis. Descriptive statistics are used to
summarize the baseline data. Spearman’s correlation coeﬃ-
cient is used to assess association between pairs of factors.
Associationsbetweenthethreepsychometricscoresandstage
of pancreatic cancer were assessed using Kruskal-Wallis tests
from analysis of variance (ANOVA). A visual examination of
repeat psychometric tests was performed.
3. Results
Demographic characteristics of the subjects enrolled in the
study are presented in Table 1. The mean age was 66 years,
and there was a nearly equal male and female ratio.
See Table 2 for a listing of the stages of pancreatic cancer.
Of the complete sample, two did not have pancreatic cancer,
one did not have a cancer diagnosis, and the other had B-cell
lymphoma.
3.1. Screening for Depressive Symptoms. Subjects com-
pleted the PHQ-9 questionnaire to evaluate for depressive
Table 1: Demographic characteristics of study subjects.
Characteristic
Gender
No. of males 12
No. of females 10
Ethnicity
No. of Caucasians 20
No. of African-Americans 1
No. of unknown 1
Age (years) Mean 65; range 52–83
Table 2: Stage of pancreatic cancer.
Stage of pancreatic cancer Number of study subjects Percent
Resectable 6 27.27
Locally, advanced, unresectable 7 31.82
Metastatic 9 40.91
symptoms and monitor the symptoms over the course of
treatment. The PHQ-9 is a series of nine questions with four
categories of frequency at which subjects experience symp-
toms. The responses to the nine questions were summed
for a score ranging from 0 to 36. Results from the PHQ
questionnaire are shown in Table 3. A score of 0–5 indicates
no major depressive symptoms, a score of 6–9 mild major
depressive symptoms, scores between 10–14 for moderate
depressive symptoms, while a score of 15–19 moderately
severe major depressive symptoms. However, 68% of the
research subjects had mild or worse major depressive symp-
toms. There were no individuals with a score of greater than
20, which would indicate severe major depressive symptoms.
With 33% of patients having moderate or moderately severe
depressive symptoms this would suggest that the largest
groups of research subjects have mild depression.
3.2. Screening for General Anxiety. The Penn State Worry
Questionnaire (PSWQ) was utilized to assess anxiety in our
population of pancreatic cancer patients. The Penn State
Worry Questionnaire is a series of ﬁfteen questions in which
respondents indicate the frequency of worrying over the past
week on a scale of 0–6. The responses are summed to a score
ranging from 0 to 90. Results from the PSWQ are shown in
Table 3. A score of 40 or less is seen in individuals with
subclinical anxiety, scores from 40 to 60 indicate moderate
anxiety of possible clinical signiﬁcance, and a score of greater
than 60 indicates a likely presence of anxiety disorder. 2 indi-
viduals had a likely anxiety disorder with large percentage of
patients demonstrating some symptoms of anxiety.
3.3. Screening for Sleep Disturbance. Sleep problems were
assessed utilizing a University of Michigan Sleep Assessment
Questionnaire (SAQ). This questionnaire assesses the fre-
quency of disturbance in participant sleeping patterns over
the past month. The scale provides a total summed score
from 0 to 26. 3 research subjects demonstrate the symptoms4 The Scientiﬁc World Journal
Table 3: Prevalence of depressive symptoms, general anxiety,
and sleep disorders in pancreatic cancer patients. MDS: major
depressive symptoms.




0–5: no MDS 9 41
6–9: mild MDS 7 32
10–14: moderate MDS 5 23
15–19: moderately severe MDS 1 5
20–36: severe MDS 0 0
General anxiety symptoms category
Data not available 1 5
<40: subclinical anxiety 12 55
40–60: moderate anxiety of possible
clinical signiﬁcance 83 6
>60: likely anxiety disorder 1 5
Prevalence of sleep disturbance
Data not available 1 5
0–10: no sleep disturbance 10 45
11–26: potential sleep problem 9 41
>26: sleep problem 2 10
of a possible sleep problem. See Table 3 for additional infor-
mation.
3.4. Interrelationship between Measures. Using Spearman
correlation, the PHQ is trended with the SAQ (Spearman’s
rho = 0.56, P-value = 0.09), which is not quite statistically
signiﬁcant at the 0.05 level that is suggestive of more
depressive symptoms in those with more severe sleep prob-
lems. We estimate that 16% of the depression score (PHQ)
variance is explained by SAQ using ANOVA. PHQ scores
were not correlated with PSWQ worry scale (Spearman’s rho
= 0.02, P-value = 0.97). SAQ did not correlate with PSWQ
(Spearman’s rho = 0.12, P-value = 0.60).
Sleep problems from the SAQ trended with stage of
cancer but were not statistically signiﬁcant (Kruskal-Wallis
statistic = 5.15, P-value = 0.08). The PHQ also trended
(Kruskal-Wallis statistic = 4.34, P-value = 0.11), and PSWQ
was not associated with stage (Kruskal-Wallis statistic = 1.46,
P-value = 0.48). There was no association of any of the three
scores with age.
The tables are a description of the data on initial
enrollment into the study. Research subjects once enrolled in
the study, all three psychometric tests were to be performed
no more frequently than once a month during follow-up
appointments. Since the follow-up evaluations were only
performed on 13 research subjects, formal analysis of the
data was not performed. Visual examination of the trends
over time in the three tests did not reveal any suggestive
patterns. However, one research subject who was moderate
MDS became moderately severe MDS during the study. All
three measures were plotted over a consistent time interval
separately with the initial survey being zero. The study was
also a complete failure in encouraging the use of tablets
by patients. By examining the audit logs, only 10% of the
patients entered their own data into the M-STRIDES system.
The other 90% ﬁlled out the paper forms, and the data was
entered by the research staﬀ.
4. Discussion
The main ﬁnding of this preliminary study is 23% of the
patientswhowerepartofthepilotprojectandhadsymptoms
of either moderately severe major depressive symptoms,
likely anxiety disorder, or a potential sleep disorder at some
point during the study. This number is calculated from the
four individuals who appear in Table 3 (one moderately
depressed, one likely anxiety disorder, and two sleep prob-
lem) and one individual becomes moderately depressed
during the longitudinal evaluation. Another two individuals
screened positive sleep disorders and anxiety at follow-up
appointment. With prevalence of symptoms, this high, rou-
tine screening and concern for patients with these illness are
appropriate. Pancreatic cancer has a very poor prognosis and
a reputation as being one of the deadliest [35]. Depression,
anxiety, and insomnia have been shown to be comorbidities
incancerpatientpopulations,andscreeninghasbeenrecom-
mended to improve the overall care of patients [36]. A num-
ber of patients also had lower severity of symptoms. While
a psychometric survey does not replace a trained clinicians,
evaluation, when patients present with this level of symp-
toms, additional investigation is warranted to clarify the
cause.
Another ﬁnding from this study which is not represented
in the statistical outcome is the routine collection of psy-
chometric data in a busy multidisciplinary pancreatic cancer
clinic. A large percentage (90%) of patients were not willing
to use the tablet PC; the routine collection of psychometric
data was accomplished through the traditional methods of
pen and paper. Concerns about the validity of the mea-
surement being conducted on the tablets are not founded
in this study; however future research is warranted. Future
trials should consider the challenges of using tablet PCs and
havealternativemethodsforasuccessfulproject.Mostcancer
centers have patient education material on psychooncology,
and referrals are common; however the use of psychometric
surveys is a more proactive approach for screening for acute
mentalhealthdisorders.Obviouslythecomplexnatureofthe
interaction between the cancer, knowledge of the diagnosis,
side eﬀects of chemo and radiation therapy, and previous
history of mental will not be revealed in a simple psycho-
metric survey; the data can help inform and engage patients
and clinicians to address concerns and seek out additional
services. While current oncology guidelines focus on distress
management [3], the nature of anxiety, depression, and sleep
disorders may not be revealed by focusing on distress. Future
studies should evaluate the diﬀerences between the distress
thermometer [3] and other Psychometric tests.
Sleep disturbance accounted for 16% of the variance in
depressive symptoms. Sleep was also more disturbed in those
with a more advanced stage of cancer. If, as we believe,
that poor sleep contributes to both poor quality of life and
increased depression in cancer patients, then there is goodThe Scientiﬁc World Journal 5
reason to pursue improving sleep in these patients. Future
studies should be signiﬁcantly powered to better describe the
relationship among these variables and to explore strategies
for improving sleep. Behavioral interventions have been
showntobeeﬀectiveinimprovingsleepinothercancers[37]
and are particularly appealing in patients already undergoing
rigorous treatment.
Compared to previous studies, the individual prevalence
of anxiety, depression, and sleep disorders appears to be
lower than previously reported [4, 6–11, 13, 26, 38–42].
While the number of participants is large in comparison
to historical reports of pancreatic cancer and depression,
the numbers are insuﬃcient for a robust statistical analysis.
Other limitations were encountered in this study. First, the
pancreaticcancerclinic atUniversity ofMichiganisareferral
location, so the initial diagnosis is often made prior to the
patients visit to the clinic. Second, a study that would verify
the claim of the presence of depression before pancreatic
tumor diagnosis would necessitate psychometric screening
be performed prior to the malignant diagnosis. Third, part
of the research protocol may have created opportunity for
participant exclusion. The treating clinicians evaluated the
potential research subjects for suitability for inclusion into
this study. If a patient was severely depressed or anxious,
an immediate referral to psychooncology would have been
made, and the research staﬀ may not have had access to
the patient for study participation. A number of diﬀerent
reasons, that this requirement was included, pertained to
cases where the patient just recently told of their diagnosis
with cancer or the patient was despondent. As the treating
clinician had the therapeutic relationship with the patient,
the study determined they were in the best position to
evaluate; this was a requirement for working in the clinic.
Fourth, no information was collected about the current
use of psychotropic drugs by the patients or the recom-
mendations for cancer treatment received by the subjects.
Additional data points about historical depression, anxiety,
and sleep disorders or other health-related events were not
recorded.
In a larger retrospective series of 258 patients with pan-
creatic cancer, depression did not aﬀect survival, although
it was common with 54 out of 258 patients (21%) with a
diagnosis and treatment for depression at the time of the
pancreatic cancer diagnosis [43]. The median survival time
for depressed patients was 4 months compared with non-
depressed patient’s median survival time of 5 months (not
signiﬁcant). There was also no association of cancer stage to
the presence of depression. These ﬁndings are in agreement
with our ﬁndings of a lack of major depressive symptoms,
anxiety, and sleep disorders in patients presenting to a
dedicated pancreatic cancer clinic. However, retrospective
diagnosis of depression can lead to lower prevalence diag-
nosis. Our prospective trial does shed some light on how
sleep, anxiety, and depression symptoms are present using
objective psychometric instruments. The lack of statistical
correlationwithsurvivaldoesnotreducetheneedtoevaluate
and treat the symptoms in patients.
It is possible that the decrease in reported psychosocial
distress in ours and in Kelsen’s studies reﬂects changes
in attitudes among pancreatic cancer patients. Another
explanation is that prior reports did not utilize a prospective,
standardized screening which was utilized here. An alternate
explanation may be that in both of our studies patients pre-
sented to a comprehensive cancer center and were therefore
motivated to seek care, which may suggest bias in our patient
population.Additionalstudyiswarrantedtofurtherevaluate
the prevalence and the correlation to improve the lives of
patients diagnosed with pancreatic cancer. Future plans to
design a larger prospective study examining the correlation
between the three comorbidities and pancreatic cancer with
comparison against a control group are needed. Additional
data collection about the treatment modalities and prior
mental health history will add additional insight into this
complex relationship.
Acknowledgments
The authors would like to thank Valencia Lyle and Deanna
Baty who assisted with the projects in numerous ways. They
would like to thank the research subjects for volunteering
their time to help better understand the correlation of
the diseases. This project was funded by the University of
Michigan Depression Center.
References
[1] A. Jemal, R. Siegel, E. Ward et al., “Cancer statistics, 2008,” CA
Cancer Journal for Clinicians, vol. 58, no. 2, pp. 71–96, 2008.
[2] W. Du, D. Touchette, V. K. Vaitkevicius et al., “Cost analysis
of pancreatic carcinoma treatment,” Cancer, vol. 89, pp. 1917–
1924, 2000.
[3] National Comprehensive Cancer Network, “NCCN Clinical
Practice Guidelines in Oncology: Distress management,”
http://www.nccn.org/professionals/physician gls/pdf/distress.
pdf.
[4] A. D. Boyd and M. Riba, “Depression and pancreatic cancer,”
Journal of the National Comprehensive Cancer Network, vol. 5,
no. 1, pp. 113–116, 2007.
[5] S. D. Passik and W. S. Breitbart, “Depression in patients with
pancreatic carcinoma. Diagnostic and treatment issues,” Can-
cer, vol. 78, pp. 615–626, 1996.
[6] I.Fras,E.M.Litin,andL.G.Bartholomew,“Mentalsymptoms
as an aid in the early diagnosis of carcinoma of the pancreas.,”
Gastroenterology, vol. 55, no. 2, pp. 191–198, 1968.
[7] E. J. Shakin and J. Holland, “Depression and pancreatic can-
cer,” Journal of Pain and Symptom Management,v o l .3 ,n o .4 ,
pp. 194–198, 1988.
[8] J. Zabora, K. Brintzenhofeszoc, B. Curbow et al., “The preva-
lence of Psychological distress by Cancer Site,” Psychooncology,
vol. 10, pp. 19–28, 2001.
[9] M. J. Massie, “Prevalence of depression in patients with can-
cer,” Journal of the National Cancer Institute. Monographs,n o .
32, pp. 57–71, 2004.
[10] N. Zilikis and C. Dervenis, “Psychosomatic aspects of pancre-
atic cancer,” Pancreatology, vol. 3, no. 4, pp. 273–275, 2003.
[11] L. Jacobsson and J. O. Ottosson, “Initial mental disorders in
carcinoma of pancreas and stomach,” Acta Psychiatrica Scan-
dinavica, vol. 221, Supplement, pp. 120–127, 1971.
[12] L. Jia, S. M. Jiang, Y. Y. Shang et al., “Investigation of
the incidence of pancreatic ancer-related depression and its6 The Scientiﬁc World Journal
relationship with the quality of life of patients,” Digestion, vol.
82, no. 1, pp. 4–9, 2010.
[13] R. Pezzilli, D. Campana, A. M. Morselli-Labate, M. C. Fabbri,
E. Brocchi, and P. Tomassetti, “Patient-reported outcomes in
subjects with neuroendocrine tumors of the pancreas,” World




Pancreas, vol. 10, no. 1, pp. 69–76, 2009.
[15] K. L. Clark, M. Loscalzo, P. C. Trask, J. Zabora, and E. J. Philip,
“Psychological distress in patients with pancreatic cancer—
an understudied group,” Psycho-Oncology, vol. 19, no. 12, pp.
1313–1320, 2010.
[16] B. T. Griﬀeth and A. Mehra, “Panic as a Harbinger of pancre-
atic cancer,” Psychosomatics, vol. 49, no. 6, pp. 538–539, 2008.
[17] S. D. Passik and A. J. Roth, “Anxiety symptoms and panic
attacks preceding pancreatic cancer diagnosis,” Psychooncol-
ogy, vol. 8, pp. 268–272, 1999.
[18] E. A. Holly, I. Chaliha, P. M. Bracci, and M. Gautam, “Signs
and symptoms of pancreatic cancer: a population-based case-
control study in the San Francisco Bay area,” Clinical Gas-
troenterology and Hepatology, vol. 2, no. 6, pp. 510–517, 2004.
[19] D. P. Kelsen, R. K. Portenoy, H. T. Thaler et al., “Pain and
depression in patients with newly diagnosed pancreas cancer,”
Journal of Clinical Oncology, vol. 13, no. 3, pp. 748–755, 1995.
[20] D.L.Musselman,A.H.Miller,M.R.Porteretal.,“Higherthan
normalplasmainterleukin-6concentrationsincancerpatients
with depression: preliminary ﬁndings,” American Journal of
Psychiatry, vol. 158, no. 8, pp. 1252–1257, 2001.
[21] M. Mayr and R. M. Schmid, “Pancreatic cancer and depres-
sion: myth and truth,” BMC Cancer, vol. 10, article 569, 2010.
[22] L. Jia, Y. Y. Shang, S. M. Jiang et al., “Relationship between
symptoms of pancreatic cancer-related depression and quality
of life of patients,” Zhonghua Yi Xue Za Zhi, vol. 89, no. 26, pp.
1847–1849, 2009.
[23] M. M. Heinen, B. A. Verhage, R. A. Goldbohm et al., “Physical
activity, energy restriction, and the risk of pancreatic cancer:
a prospective study in the Netherlands,” The American Journal
of Clinical Nutrition, vol. 94, pp. 1314–1323, 2011.
[24] Y. Bao and D. S. Michaud, “Physical activity and pancreatic
cancer risk: a systematic review,” Cancer Epidemiology Bio-
markers and Prevention, vol. 17, no. 10, pp. 2671–2682, 2008.
[25] J. C. Yaskin, “Nervous symptoms as earliest manifestations of
carcinoma of the pancreas,” Journal of the American Medical
Association, vol. 96, pp. 1664–1668, 1931.
[26] R. T. Joﬀe, D. R. Rubinow, and K. D. Denicoﬀ, “Depression
and carcinoma of the pancreas,” General Hospital Psychiatry,
vol. 8, no. 4, pp. 241–245, 1986.
[27] J. C. Holland, A. H. Korzum, and S. Tross, “Comparative psy-
chological disturbance in patients with pancreatic and gastric
cancer,” American Journal of Psychiatry, vol. 143, no. 8, pp.
982–986, 1986.
[ 2 8 ] C .P .C a r n e y ,L .J o n e s ,R .F .W o o l s o ne ta l . ,“ R e l a t i o n sb e t w e e n
depression and pancreatic cancer in the general population,”
Psychosomatic Medicine, vol. 65, pp. 884–888, 2003.
[29] M. J. Sateia and B. J. Lang, “Sleep and cancer: recent devel-
opments,” Current Oncology Reports, vol. 10, no. 4, pp. 309–
318, 2008.
[30] K. Suzuki, M. Miyamoto, T. Miyamoto, and K. Hirata, “Insuli-
noma with early-morning abnormal behavior,” Internal Med-
icine, vol. 46, no. 7, pp. 405–408, 2007.
[31] C. C. Reyes-Gibby, W. Chan, J. L. Abbruzzese et al., “Patterns
of self-reported symptoms in pancreatic cancer patients
receiving chemoradiation,” Journal of Pain and Symptom
Management, vol. 34, no. 3, pp. 244–252, 2007.
[32] K. Kroenke, R. L. Spitzer, and J. B. W. Williams, “The PHQ-
9: validity of a brief depression severity measure,” Journal of
General Internal Medicine, vol. 16, no. 9, pp. 606–613, 2001.
[ 3 3 ]T .J .M e y e r ,M .L .M i l l e r ,R .L .M e t z g e r ,a n dT .D .B o r k o v e c ,
“Development and validation of the Penn State Worry Ques-
tionnaire,” Behaviour Research and Therapy,v o l .2 8 ,n o .6 ,p p .
487–495, 1990.
[34] Department of Psychiatry, Michigan Clinical Outcomes and
Research Engine (M-Strides), http://www.psych.med.umich
.edu/MentalHealthServices/m-strides.asp.
[35] Surveillance Epidemiology and End Results (SEER), National
Cancer Institute, 2006.
[36] S. D. Passik, K. L. Kirsh, D. Theobald et al., “Use of a depres-
sion screening tool and a ﬂuoxetine-based algorithm to
improvetherecognitionandtreatmentofdepressionincancer
patients: a demonstration project,” Journal of Pain and Symp-
tom Management, vol. 24, no. 3, pp. 318–327, 2002.
[37] A. M. Berger, B. R. Kuhn, L. A. Farr et al., “Behavioral therapy
intervention trial to improve sleep quality and cancer-related
fatigue,” Psycho-Oncology, vol. 18, no. 6, pp. 634–646, 2009.
[38] N. Pomara and S. Gershon, “Treatment-resistant depression
in an elderly patient with pancreatic carcinoma: case report,”
Journal of Clinical Psychiatry, vol. 45, no. 10, pp. 439–440,
1984.
[39] C. Savage, W. Butcher, and D. Noble, “Psychiatric manifesta-
tions in pancreatic disease,” Journal of Clinical and Experimen-
tal Psychopathology, vol. 13, pp. 9–16, 1952.
[40] C. Savage and D. Noble, “Cancer of the pancreas; two cases
simulating psychogenic illness.,” The Journal of Nervous and
Mental Disease, vol. 120, no. 1-2, pp. 62–65, 1954.
[41] I. Fras and E. M. Litin, “Comparison of psychiatric manifesta-
tions in carcinoma of the pancreas, retroperitoneal malignant
lymphoma, and lymphoma in other locations,” Psychosomat-
ics, vol. 8, no. 5, pp. 275–277, 1967.
[42] G. D. Wallen, F. H. Connolly, and N. L. Gittleson, “A case of
carcinoma of the pancreas with a psychiatric presentation.,”
British Journal of Clinical Practice, vol. 26, no. 3, pp. 132–133,
1972.
[43] S. Sheibani-Rad and V. Velanovich, “Eﬀects of depression on
the survival of pancreatic adenocarcinoma,” Pancreas, vol. 32,
no. 1, pp. 58–61, 2006.